JACOBSON PHARMA

2633
0.9051.63% ( -0.015 )
Delay Closed: Nov 16, 16:08:00

Overview

JACOBSON PHARMA (2633)

Jacobson Pharma Corporation Limited, through its subsidiaries, engages in the development, production, marketing, and sale of essential medicines and specialty...

Open
0.915
High
0.915
Low
0.905
Prev. Close
0.920
Volume
276.00K
Turnover
250.86K
Avg Price
0.909
Bid/Ask Ratio
94.12%
Amplitude
1.09%
52wk High
1.400
Volume Ratio
0.53
Turnover Ratio
0.01%
52wk Low
0.905
HK Mkt Cap
1.81B
Market CapHKD
1.81B
P/ETTM
6.00
P/EDynamic
6.00
P/EStatic
--
EPSTTM
0.151
EPSDynamic
0.151
EPSStatic
--
BVPS
1.16
P/B
0.78
HK Shares
2.00B
Dividend YieldTTM
9.94%
DividendTTM
0.09
Shares
2.00B
Min lot size
2,000
Currency
HKD

JACOBSON PHARMA Analyst Rating

View more

Forecast & Rating

Aug 28, 2026
Price forecast
HK$2.06127.07%
Forecast & RatingStrong buy
1analysts
  • Strong buy100.00%
  • Buy0.00%
  • Hold0.00%
  • Sell0.00%
  • Strong sell0.00%

Daily Events

  1. Nov, 16

    Jacobson Pharma closed at HK$0.905 today, marking a 52-week low that reflects sustained cooling in investor sentiment. The stock has tumbled 29.84% year-to-date from HK$1.29 and trades 39.26% below its 52-week peak of HK$1.49. From a fundamental perspective, Q4 revenue reached HK$401.5 million with 4.7% year-over-year growth; however, operating profit contracted sharply by 11.52% to HK$101.9 million, signaling margin compression. Net profit stood at HK$79.8 million. Market engagement remains subdued, with today's turnover totaling only HK$2.51 million and a turnover rate of just 0.01%, indicating waning investor interest. Technically, the stock has breached its 60-day moving average of HK$0.97 and now trades near the 52-week low support level. On valuation, a P/E of 6.0x and P/B of 0.78x suggest the stock trades below book value; however, the ongoing contraction in operating margins coupled with anemic trading volumes suggest the market lacks conviction in near-term growth prospects.

  2. Nov, 13

    Jacobson Pharma held flat at HK$0.92 today while hitting fresh 52-week lows, with paper-thin trading volume—the morning session saw zero turnover, with merely 16,000 shares transacting in late afternoon. The stock has slumped 28.7% year-to-date and 38.3% from its 52-week high of HK$1.49, reflecting sustained selling pressure and shallow liquidity. Recent quarterly results show operating revenue of HK$401 million, up 4.7% year-over-year, but operating profit declined 11.5%, signaling margin compression. Despite a low valuation—P/E of 6.1x and P/B of 0.79x—the market remains concerned about slowing profit growth and weak investor sentiment.

  3. Nov, 12

    Jacobson Pharma closed marginally lower at HK$0.92 today, declining slightly from the opening price of HK$0.925, reflecting persistent market pessimism. The stock recently hit a 52-week low of HK$0.915, having fallen 28.68% year-to-date and retreated 38.26% from its 52-week peak of HK$1.49, now trading at historic lows. Latest quarterly earnings showed revenue growth of 4.7% year-over-year, yet operating profit declined 11.52% and net profit growth slowed to -0.6%, representing the primary pressure on the stock. Despite an extremely compressed valuation with PE of just 6.1x and PB of 0.79x, plus a 9.78% dividend yield and robust 19.88% net margin, investors remain concerned about the deceleration in earnings growth.

  4. Nov, 11

    Jacobson Pharma held steady at HK$0.920 throughout the session, with both morning and afternoon trading showing minimal activity. The stock recently touched a 52-week low of HK$0.915, and while today's price sits slightly above that floor, it has fallen 28.68% year-to-date from the HK$1.29 opening level and 38.26% below the 52-week high of HK$1.49. On fundamentals, the latest period showed operating revenue growing 4.7% year-on-year to HK$401.5 million with a stable net margin of 19.88%, yet operating profit declined 11.52% and earnings per share slipped 1.17%, indicating earnings pressure. Valuation metrics are compressed at a P/E of 6.1 and P/B of 0.79, near historical lows. However, trading volume has dried up with only 56,000 shares traded and HK$51,520 in daily turnover, reflecting diminished market interest and confidence in the company.

  5. Nov, 10

    Following yesterday's 52-week low of HK$0.915, the stock opened at HK$0.920 this morning and held stable through the morning session, then dipped back to HK$0.915 in afternoon trading before rebounding to close at HK$0.920. The price remains deeply oversold, having declined 28.68% year-to-date and now trading 38.26% below the 52-week high of HK$1.49, well beneath both the 20-day MA of HK$0.942 and 60-day MA of HK$0.977. Latest Q4 results showed operating revenue of HK$401.5 million, up 4.7% YoY, but operating profit of HK$101.9 million fell 11.52% YoY, signaling profitability pressure. With valuation metrics at extremely attractive levels—PE of just 6.1x, PB of 0.79x, and dividend yield of 9.78%—such deep undervaluation may be drawing interest. However, turnover of just 0.01% signals minimal market participation, leaving the sustainability of this rebound uncertain, while improvement in operating margins remains a critical challenge ahead.

News